Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 14/20 | 0.82 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.75 |
| ▸ | PDE4A | P27815 | 4/20 | 0.58 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.58 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187573 | 0.95 | PDE10A (0.84) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL7887712 | 0.91 | PDE10A (0.91) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL7887144 | 0.90 | PDE10A (1.00) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL12027370 | 0.90 | PDE10A (0.82) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL3269746 | 0.89 | PDE10A (0.80) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL30123155 | 0.89 | PDE10A (0.80) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL3271247 | 0.88 | PDE10A (0.79) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL30123420 | 0.88 | PDE10A (0.79) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL24950836 | 0.87 | PDE10A (0.74) | PDE10ALGALS3PDE4DPDE4APDE4B | |
| SCHEMBL30201958 | 0.87 | PDE10A (0.74) | PDE10ALGALS3PDE4DPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400991-A1 | RADIOLABELLED PDE10 LIGANDS | Janssen Pharmaceutica, N.V. (BE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110305637-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA N.V. | 2011-12-15 | — | — | US | disclosed |
| US-20110305637-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA N.V. | 2011-12-15 | — | — | US | disclosed |
| US-20110305637-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA N.V. | 2011-12-15 | — | — | US | disclosed |
| WO-2010097367-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097367-A1 | RADIOLABELLED PDE10 LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305637-A1 | RADIOLABELLED PDE10 LIGANDS | PDE9A, PDE10A, PDE7A | PDE10A 2/4885LGALS3 2710/4885PDE4D 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.